tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Palvella Therapeutics price target raised to $190 from $105 at Truist
PremiumThe FlyPalvella Therapeutics price target raised to $190 from $105 at Truist
5d ago
Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics’ QTORIN Rapamycin
Premium
Ratings
Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics’ QTORIN Rapamycin
6d ago
Palvella Therapeutics price target raised to $200 from $190 at H.C. Wainwright
Premium
The Fly
Palvella Therapeutics price target raised to $200 from $190 at H.C. Wainwright
6d ago
Palvella Therapeutics announces topline results from Phase 2 TOIVA trial
PremiumThe FlyPalvella Therapeutics announces topline results from Phase 2 TOIVA trial
6d ago
Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments in DSAP Treatment
Premium
Ratings
Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments in DSAP Treatment
16d ago
Palvella Therapeutics: Promising Biopharmaceutical Growth with QTORIN Platform Advancements
Premium
Ratings
Palvella Therapeutics: Promising Biopharmaceutical Growth with QTORIN Platform Advancements
16d ago
Palvella Therapeutics price target raised to $145 from $87 at Stifel
PremiumThe FlyPalvella Therapeutics price target raised to $145 from $87 at Stifel
27d ago
Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Premium
The Fly
Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James
1M ago
Palvella Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
Premium
Ratings
Palvella Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100